Clinical Trial Update: A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations

View source ↗

Summary

A prospective cohort trial evaluating pralsetinib or anlotinib for locally advanced or metastatic medullary thyroid carcinoma with RET mutations; recruitment ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• GAVRETO (pralsetinib)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Medullary Thyroid Cancer (MTC) | Status: NOT_YET_RECRUITING